A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

Summary

NTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Timeline

Start

2025-01-23

Primary completion

2025-07-08

Completion

2027-07-08

Drugs

Indications